CELLINK to partner with Made In Space to advance bioprinting technology in space

CELLINK today announced its partnership with Made In Space, Inc. (MIS), the industry leader for space manufacturing technologies, to develop advanced bioprinting technology for space. The partnership looks to combine MIS expertise in additive manufacturing in microgravity with CELLINK’s innovative bioprinting technologies and leverage the microgravity environment to gain insights that could improve drug screening and cancer research on Earth. 

“CELLINK supports space programs in the United States with our deep commitment to cutting-edge innovation, extensive portfolio of technologies and world-class team of scientists and engineers,” said CELLINK co-founder and CEO Erik Gatenholm. “We are excited to partner with Made In Space to refine bioprinting technologies that can support and enhance future missions in spaceflight and space exploration.”

Through this strategic partnership, CELLINK and MIS intend to align their technical competencies and identify technology development opportunities across several pathways including the International Space Station and future platforms.

Bioprinting has the potential to mitigate crew health and safety risks on long-duration spaceflight missions where access to standard medical facilities isn’t readily available. Bioprinting capabilities optimized to operate in the space environment could enable future crews to develop skin and bone patches to aid in wound healing in space. 

CELLINK has prior experience in space and worked with the Swedish National Space Agency and Uppsala University to launch bioprinted stem cells on a suborbital flight onboard the MASER 14 vehicle in June 2019.

MIS was founded in 2010 and has pioneered space manufacturing capabilities in space dating back to the first demonstration of additive manufacturing in space in 2014. The company’s mission is to industrialize low-Earth orbit and support future space exploration through on-orbit manufacturing and assembly and materials development. 


For more information, please contact:

Erik Gatenholm, CEO                                               Gusten Danielsson, CFO
Phone: EU +46 73 267 00 00                                   Phone: +46 70 991 86 04
US +1 (650) 515 5566                                              US +1 (857) 332 2138
Email:                                             Email:



CELLINK is the leading 3D bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK. Erik Penser Bank AB is the company’s certified adviser, available by phone at +46 846 383 00 and by email at:

Följande bilagor finns för nedladdning:

Se fullständigt pressmeddelande och andra nyheter från detta bolag på Cision News.
Vill du också synas med dina nyheter på
Läs mer om publicering på

Vi använder cookies för att förbättra funktionaliteten på våra sajter, för att kunna rikta relevant innehåll och annonser till dig och för att vi ska kunna säkerställa att tjänsterna fungerar som de ska. Läs mer i vår cookiepolicy.
Läs mer

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

  • Full tillgång till med nyheter och analyser

  • Tillgång till över 1100 aktiekurser i realtid

  • Innehållet i alla Di:s appar, tjänster och nyhetsbrev

3 månader för
197 kr
Spara 1000 kr


Redan prenumerant?